Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

St Kilda, Australia Clinical Trials

A listing of St Kilda, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (67) clinical trials

Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals

The co-EC study aims to to enhance HCV care and treatment among HIV-infected individuals through a predominantly nurse-led model of care in primary care as well as hospital settings. It involves: A nurse-led model of care in primary health care to increase access to PBS HCV treatment with interferon-free HCV ...

Phase N/A

0.0 miles

Learn More »

Dimethyl Fumarate (DMF) Observational Study

Patients aged 12 to under 18 may be included where enrollment of pediatric patients in this study is considered observational and is permissible by local regulations.

Phase N/A

1.05 miles

Learn More »

HIV Persistence in Lymph Node and Peripheral Blood

Combination antiretroviral therapy (ART) has significantly improved the immune function of HIV infected individuals and has transformed a fatal disease into a chronic infection for those with access to ART. Despite suppressing HIV-1 replication, ART is not curative and nearly all HIV infected individuals experience viral rebound within weeks or ...

Phase N/A

1.05 miles

Learn More »

Urotensin II and Vascular Tone in Cirrhosis

This study looks at the iontophoresis of urotensin II in chronic liver disease patients.

Phase N/A

1.05 miles

Learn More »

Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection

Background and Research Plan: Chronic HCV infection often follows a progressive course over many years, and can ultimately result in cirrhosis and the need for liver transplantation or hepatocellular carcinoma. The decision to treat patients with chronic hepatitis C infection is based upon several factors including the natural history and ...

Phase N/A

1.05 miles

Learn More »

Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry

To learn in a general Cardiac Resynchronization Therapy Defibrillators (CRT-D) population, which optimization techniques are used and how effective they are. It will compare 12-month response rates among different optimization methods and characterize which selected subject subgroups achieve better response than others. A subset of SMART Registry subjects will contribute ...

Phase N/A

2.34 miles

Learn More »

Australian and New Zealand Massive Transfusion Registry

Severe and unstopped blood loss can occur for a number of different reasons including after a serious injury, delivery of a baby and following other medical and surgical emergencies. The investigators understanding of how to best treat people with serious bleeding is still incomplete, with many questions remaining. These include ...

Phase N/A

2.34 miles

Learn More »

Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment

208 subjects (i.e., 137 per surgical group; 71 per conservative group) with TL burst fractures AOSpine classification type A3 or A4 without neurological deficit as defined in the inclusion/exclusion criteria, and with or without suspected Posterior Ligament Complex (PLC) injury (M1) from T10 to L2, will be enrolled in a ...

Phase N/A

2.34 miles

Learn More »

A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.

Phase N/A

2.34 miles

Learn More »

Tysabri Observational Program

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment ...

Phase N/A

2.34 miles

Learn More »